Cytosorbents.
company
- Reports this week
- 0
- Active events
- 0
- Connections
- 20
What's happening
One to three months ago
-
Cytosorbents held an investor conference in New York City.Some support1 report
-
The FDA upheld the De Novo denial for DrugSorb-ATR, a product of CytoSorbents. Phillip Chan serves as the company's CEO.Well supported7 reports
-
Cytosorbents is facing market challenges in Germany and the Middle East, which CEO Phil Chan has addressed.Some support3 reports
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Cytosorbents this week
News at the entities that move Cytosorbents most-
FDA StructuralFDA, LabCorp, and Charles River Laboratories formed a collaboration to evaluate the potential for medicine abuse.Moves Cytosorbents
-
AstraZeneca OperationalAstraZeneca is relocating its registered office from Karnataka to Bengaluru, citing proximity to policy and financial ecosystems.Moves Cytosorbents
-
Nasdaq StructuralCompany Q783794 made an announcement originating from Lafox, Illinois, and is listed on Nasdaq.Moves Cytosorbents
-
New York City Shared contextLigand CEO hosted an Investor Day in New York City on October 1, 2026.Moves Cytosorbents
-
Automated Insights Mentioned togetherAutomated Insights generated a story using data on August 28, 2025, while located in San Jose.Moves Cytosorbents
-
Middle East Shared contextTensions in the Middle East are now impacting the French economy.Moves Cytosorbents
Connections
The 10 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Phillip Chan Structural
Phillip Chan holds the formal role of Chief Executive Officer of Cytosorbents.
-
FDA Structural
FDA regulates Cytosorbents' drug submissions, issuing denials and providing market authorization guidance.
-
Phil Chan Structural
Phil Chan serves as the CEO of Cytosorbents, establishing a leadership and functional dependency.
-
Tom Shannon Structural
Cytosorbents appointed Tom Shannon as VP of Marketing to lead marketing strategy for DrugSorb-ATR.
-
AstraZeneca Operational
Cytosorbents' drug product is clinically used alongside AstraZeneca's Brilinta in patients.
-
S. Lee Operational
S. Lee provides financial forecasts and analysis regarding Cytosorbents' earnings.
-
Nasdaq Structural
Cytosorbents must maintain minimum bid price requirements to remain listed on the Nasdaq exchange.
-
New York City Shared context
Cytosorbents holds an investor conference within New York City.
Show all 10 connections
-
Automated Insights Mentioned together
Automated Insights utilizes Cytosorbents' company data to generate financial stories and earnings snapshots.
-
Middle East Shared context
The evidence discusses the general business outlook of the Middle East but does not mention Cytosorbents.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
1 eventJune 2026
4 events- The FDA upheld the De Novo denial for DrugSorb-ATR, a product of CytoSorbents. Phillip Chan serves as the company's CEO.
- Cytosorbents is conducting research and commercialization in the US and Germany.
- Sales growth for Cytosorbents was driven by Germany on August 14, 2025.
- CytoSorbents will present at a conference on September 5, 2025.